Drugs / NeoMTA nusmile
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03545139 | Sep 2019 → Sep 2020 | — | Cairo University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeoMTA nusmile | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03545139 ↗ |
| Known as | NeoMTA | “The new formulation of MTA (NeoMTA) does not contain bismuth oxide, will be used in revascularization of nonvital immature permanent anterior teeth.” NCT03545139 ↗ |
| Modality | Other / unclassified | “A new formulation of MTA was developed in which bismuth oxide was omitted.” NCT03545139 ↗ |